Recent pharma happenings:
MyoKardia has announced the promising results of Phase III clinical trials of its lead drug Mavacamten for symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
AstraZeneca and Merck’s Lynparza (olaparib) in combination with Roche’s Avastin (bevacizumab) receives FDA approval for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
Dyno Therapeutics has announced the launch of its proprietary CapsidMap platform to design novel adeno-associated virus (AAV) vectors.
Abbott Laboratories has won EUA for its diagnostic kit – SARS-CoV-2 IgG lab-based serology blood test on the Alinity i system for COVID-19.

For more detailed information visit:
https://www.delveinsight.com/blog/recent-pharma-happenings-for-astrazeneca-abbott-merck-myokardia/